trial

Shared Decision Making for Patients With First-admission Schizophrenia

NCTId NCT01869660
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 23 (actual)
Sponsored by Yokohama City University
Primary completion 2015-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
23 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2013-06
Primary completion
2015-04
Eligibility
ALL · 16 Years · 65 Years

Interventions & indications

Drugs
Shared Decision Making

Sponsors

Yokohama City UniversityLead Sponsor

Investigators

1
Yoshio Hirayasu, PhDStudy Chair

Sites

1 total
Numazu, Japan

Linked catalysts

1
Shared Decision Making for Patients With First-admission Schizophrenia — primary completion2015-04

Facts & assertions

4 sourced
Enrollment
23
Phase
PHASE2,PHASE3
Primary Completion Date
2015-04
Status
COMPLETED
relationships
The graph out of here
drug
Shared Decision Making
drug
lead_sponsor
Yokohama City University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Yoshio Hirayasu, PhD
person